CA2203379C - Inhibiteurs de cgmp-pde destines au traitement du dysfonctionnement erectile - Google Patents

Inhibiteurs de cgmp-pde destines au traitement du dysfonctionnement erectile Download PDF

Info

Publication number
CA2203379C
CA2203379C CA 2203379 CA2203379A CA2203379C CA 2203379 C CA2203379 C CA 2203379C CA 2203379 CA2203379 CA 2203379 CA 2203379 A CA2203379 A CA 2203379A CA 2203379 C CA2203379 C CA 2203379C
Authority
CA
Canada
Prior art keywords
alkyl
radical
hydrogen
substituted
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA 2203379
Other languages
English (en)
Other versions
CA2203379A1 (fr
Inventor
Simon Fraser Campbell
Alexander Roderick Mackenzie
Anthony Wood
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Research and Development Co NV SA
Original Assignee
Pfizer Research and Development Co NV SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB9423910A external-priority patent/GB9423910D0/en
Application filed by Pfizer Research and Development Co NV SA filed Critical Pfizer Research and Development Co NV SA
Publication of CA2203379A1 publication Critical patent/CA2203379A1/fr
Application granted granted Critical
Publication of CA2203379C publication Critical patent/CA2203379C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Ces composés qui sont des inhibiteurs sélectifs des cGMP PDE (guanosine 3',5'-monophosphate cyclique phosphodiestérase) sont utiles dans le traitement du dysfonctionnement érectile (impuissance) chez les animaux mâles, notamment chez l'homme.
CA 2203379 1994-11-26 1995-10-16 Inhibiteurs de cgmp-pde destines au traitement du dysfonctionnement erectile Expired - Fee Related CA2203379C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9423910.0 1994-11-26
GB9423910A GB9423910D0 (en) 1994-11-26 1994-11-26 Therapeutic agents
PCT/EP1995/004066 WO1996016644A1 (fr) 1994-11-26 1995-10-16 INHIBITEURS DE cGMP-PDE DESTINES AU TRAITEMENT DU DYSFONCTIONNEMENT ERECTILE

Publications (2)

Publication Number Publication Date
CA2203379A1 CA2203379A1 (fr) 1996-06-06
CA2203379C true CA2203379C (fr) 2006-01-03

Family

ID=29403918

Family Applications (1)

Application Number Title Priority Date Filing Date
CA 2203379 Expired - Fee Related CA2203379C (fr) 1994-11-26 1995-10-16 Inhibiteurs de cgmp-pde destines au traitement du dysfonctionnement erectile

Country Status (1)

Country Link
CA (1) CA2203379C (fr)

Also Published As

Publication number Publication date
CA2203379A1 (fr) 1996-06-06

Similar Documents

Publication Publication Date Title
US6300335B1 (en) 4-aminoquinazoline derivative cGMP-PDE inhibitors for the treatment of erectile dysfunction
US20200325130A1 (en) Proteolysis Targeting Chimera Compounds and Methods of Preparing and Using Same
JP6247249B2 (ja) 眼障害のためのｐｄｅ１阻害剤
US10058539B2 (en) Pharmaceutical compositions containing a PDE4 inhibitor and a PI3 delta or dual PI3 delta-gamma kinase inhibitor
ES2312568T3 (es) Combinaciones antineoplasicas que comprenden cci-779 (derivado de rapamicina) junto con gemcitabina o fluoruracilo.
RU2294762C2 (ru) Фармацевтическая композиция, промотирующая дефекацию
CA2450777C (fr) Utilisation d'inhibiteurs c-src seuls ou en combinaison avec sti571 pour le traitement de leucemies
TW200538128A (en) Therapeutic combinations of atypical antipsychotics with corticotropin releasing factor antagonists
JP2014028869A (ja) 脂質キナーゼおよびｍＴＯＲのデュアル阻害剤としてのイミダゾキノリン
CA3064247A1 (fr) Inhibiteurs des janus kinases pour le traitement du syndrome de l'oeil sec et autres maladies de l'oeil
WO1994028902A1 (fr) Pyrazolopyrimidinones utilisees pour traiter l'impuissance
JP2007332156A (ja) 性的不能の治療に有効な組合せ
JP2020105181A (ja) 同種抗体により駆動される慢性移植片対宿主病を処置及び予防する方法
JP4778894B2 (ja) 不安障害の治療方法
US6436944B1 (en) Combination effective for the treatment of impotence
JP2008501007A (ja) 異常な細胞増殖を治療するための方法
CA2203379C (fr) Inhibiteurs de cgmp-pde destines au traitement du dysfonctionnement erectile
EP1136072A1 (fr) Preparations destinees a etre administrees par voie uretrale
MXPA00009614A (en) Combination effective for the treatment of impotence comprising a potassium-channel-opener and a cgmp elevator
ZA200700129B (en) Combination of a selective noradrenaline reuptake inhibitor and a PDEV inhibitor
JP2002249446A (ja) 不能の治療に効果的な多剤併用薬
MXPA06009271A (en) Therapeutic combinations of atypical antipsychotics with corticotropin releasing factor antagonists

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed